New study advances cancer precision therapies by identifying patients who benefit from Bexmarilimab treatment
Researchers at the University of Turku, Finland, have taken a step towards more personalised and effective cancer treatments. A new study has identified the conditions under which the antibody drug bexmarilimab can activate the body's own defence system against cancer, and how to identify patients who will benefit from the drug. The study was published in the Journal for ImmunoTherapy of Cancer.